White House MAHA Report may have garbled science by using AI, experts say
Some of the citations that underpin the science in the White House's sweeping 'MAHA Report' appear to have been generated using artificial intelligence, resulting in numerous garbled scientific references and invented studies, AI experts said Thursday.
Of the 522 footnotes to scientific research in an initial version of the report sent to The Washington Post, at least 37 appear multiple times, according to a review of the report by The Washington Post. Other citations include the wrong author, and several studies cited by the extensive health report do not exist at all, a fact first reported by the online news outlet NOTUS on Thursday morning.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
14 minutes ago
- Yahoo
T&C Horoscopes: June 1—15
June 1—15: On the 5th and the 8th your plans will be shaping up nicely, but by the 9th unwelcome realities will intrude, with Saturn, Pluto, and Neptune blocking the way, so be patient. The full Moon of the 11th lights up your relationship angle, and emotionally charged situations come to some sort of fruition. Be ready to regroup on the 1—15: The 5th promises to be an encouraging time, and the 8th is full of enthusiasm and good prospects—so do and dare. Unfortunately, perspective-shifting events have the power to sink your fortunes near the 8th and 9th, but you're best off waiting and seeing and focusing on important plans and projects on the 11th. The 11th is also a time to smooth out wrinkles resulting from skewed communications, and change is in the 1—15: Mars in your sign makes you more aggressive than usual, and you can clear up some issues and cut through any resistance from the 4th to the 7th. The 9th and 10th, though, are another story, and as you bump into obstacles you'll need to reroute your plans and make an effort to redefine your goals. The full Moon of the 11th lights up the most playful angle of your chart, and you should try to avoid impulsive actions on the 1—15: The 4th and 5th are times to set new goals, and the 8th is a time to expand your horizons. Try not to get discouraged by difficult situations that crop up near the 9th, though, because the picture will soon be changing. The full Moon in Sagittarius will be shining in the most personal part of your solar chart, drawing attention homeward, and the 15th brings a certain chaos to bear on everyone's 1—15: Whatever occurs near the 4th and 7th will help guide you in a more favorable direction. With uplifting Jupiter entering the sign of Cancer on the 9th, you'll be starting a new phase professionally and publicly. Three nasty aspects happening near the 9th will momentarily throw all plans into disarray, but the full Moon of the 11th resets your compass and lifts your 1—15: Positive aspects make the 5th an opportune and enjoyable time, and on the 6th Venus enters your solar relationship angle, bringing more romance and affection your way for some time. But despite your good intentions on the 8th, be ready for misunderstandings to happen near the 9th. The full Moon of the 11th activates your financial angle, and aspects warn you to avoid impulsive moves on the 14th and 1—15: Try to get out and about on the 4th and 5th and connect. The 7th and 8th are days when arrangements fall into place, and good communication creates stronger bonds. But three disharmonious aspects happening on the 9th stir up resentments and withdrawals. With the full Moon of the 11th falling in your birth sign, though, your ebullient nature and fiery warmth melt any opposition. The 15th is a time to be more conservative and 1—15: Favorable aspects from the 5th through the 8th mean fairly smooth sailing personally and professionally, but the 9th holds some unpleasant encounters and discoveries—so don't overreact. The good news is that Jupiter will then enter your relationship angle for a long stay, indicating that more support and affection will be heading your way. The period from the 11th to the 15th is a good time to go 1—15: Understandings and favorable deals are accented on the 4th and 5th, and the 7th and 8th hold creative and social magic. Everyone is likely to be out of sorts for various reasons on the 9th, when the planets are highly disharmonious. With the bright full Moon of the 11th lighting up the part of your solar chart that's all about the future and new plans, get inspired and follow your dreams. Whatever occurs near the 15th is not an indication that you are on the wrong 1—15: The 4th and 5th are days to get out and accomplish exactly what you set out to do, and with Mercury aspected by lucky Jupiter, the 7th and 8th hold good news. Unfortunately, the 9th brings complexities and resistance that are telling you to stop in your tracks and wait and see. But the full Moon of the 11th in jaunty Sagittarius is a game changer. Try to remain cautious on the 14th and 15th, even if you're tempted to be 1—15: The 3rd through the 5th hold positive energy for you, so go after your goals and enjoy life fully. The ideas you come up with near the 7th promise to take you far, but near the 9th events will be challenging, slowing your progress momentarily. Aspects near the full Moon of the 11th are spirit-lifting, and then near the 14th and 15th it's time to think before you act, or risk running into 1—15: Fresh ideas and plans will be capturing your imagination from the 4th through the 8th, but new information and unexpected events near the 9th will be telling you to reexamine what you're hoping to put in place. You'll be able to gain more clarity near the 11th, and the full Moon shines on shared finances and constructive progress. The energy near the 15th is highly volatile, though, so try to be patient. You Might Also Like 12 Weekend Getaway Spas For Every Type of Occasion 13 Beauty Tools to Up Your At-Home Facial Game
Yahoo
17 minutes ago
- Yahoo
1 dead, 11 injured in mass shooting at North Carolina house party: Sheriff
One person was killed and at least 11 others injured early Sunday when gunfire broke out during a house party in Catawba County, North Carolina, authorities said. The shooting occurred at around 12:45 a.m. at a residence in Mountain View, about 60 miles northwest of Charlotte, according to a social media statement posted by the Catawba County Sheriff's Office. Investigators told ABC Charlotte affiliate station WSOC that the shooting erupted at residence where a party attended by as many as 100 people was in progress. Investigators said they suspect that one or more people discharged firearms. Catawba County sheriff's deputies and officers from the nearby Hickory Police Department went to the house after receiving reports of multiple people being shot, according to the sheriff's office statement. One of the shooting victims was pronounced dead, authorities said. Of the 11 others wounded, one was in critical condition and several remained hospitalized, officials said. MORE: 2 killed, including officer, in California shooting, sheriff says No arrests have so far been announced. Investigators from the Hickory Police Department and special agents with the North Carolina State Bureau of Investigation were at the scene of the shooting Sunday morning attempting to establish a motive for the deadly violence and identify those responsible, according to the statement from the sheriff's department. Witnesses told WSOC that many of those attending the party were local high school students. "As soon as I heard the shots everybody started scattering off, ducking our heads, running off toward our cars toward safety. And I called my friend and he said 'call 911. I need help,'" one of the teenage partygoers told WSOC. This is a developing story. Please check back for updates. 1 dead, 11 injured in mass shooting at North Carolina house party: Sheriff originally appeared on
Yahoo
19 minutes ago
- Yahoo
Initial Data from the ARC-20 Study of Casdatifan Plus Cabozantinib Showed Nearly Half of Patients with Metastatic Kidney Cancer Had a Confirmed Response
Treatment with casdatifan, a HIF-2a inhibitor, plus cabozantinib, a tyrosine kinase inhibitor, showed a confirmed overall response rate (ORR) of 46% in patients who reached a minimum of 12 weeks (two scans) of follow-up The combination had a manageable safety profile, and there was no meaningful overlapping toxicity for the two drugs These data support the initiation of PEAK-1, a Phase 3 study that will evaluate casdatifan plus cabozantinib in immunotherapy-experienced clear cell renal cell carcinoma (ccRCC) patients, and eVOLVE-RCC02, a Phase 1b/3 study in first-line ccRCC patients, both of which will begin shortly Arcus will host a conference call to discuss these data at 5:00 AM PT / 7:00 AM CT on Monday, June 2, 2025 HAYWARD, Calif., June 01, 2025--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today presented the first data for casdatifan plus cabozantinib in an oral presentation by Dr. Toni K. Choueiri, Dana-Farber Cancer Institute, at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. "I was very encouraged to see that nearly half of patients had a confirmed response to the casdatifan plus cabozantinib combination despite short follow-up," said Toni K. Choueiri, M.D., director of the Lank Center for Genitourinary (GU) Oncology at Dana-Farber, the Jerome and Nancy Kohlberg Chair and professor of medicine at Harvard Medical School, and lead investigator of ARC-20. "Casdatifan plus cabozantinib was well tolerated, and the safety profile was consistent with that of either agent alone, supporting their potential as a combination therapy. I look forward to enrolling patients into the PEAK-1 trial as soon as it is open." "The initial data for casdatifan plus cabozantinib in the ARC-20 study have already exceeded the historic benchmarks for either agent alone, as well as that of another HIF-2a inhibitor plus cabozantinib in the same second-line setting," said Terry Rosen, Ph.D., chief executive officer of Arcus. "These data serve as the proof of concept for PEAK-1, which will be initiated in the coming weeks and is designed to generate evidence to change the standard of care for people who have progressed on prior immunotherapy treatment." ARC-20 is a Phase 1/1b dose-escalation and expansion study that includes a cohort evaluating once-daily 100mg of casdatifan plus 60mg of cabozantinib in patients with ccRCC who had progressed on prior immunotherapy. At the time of the data cutoff (DCO, March 14, 2025), 42 participants were evaluable for safety, and 24 reached at least 12 weeks of follow-up and were evaluable for efficacy. Among the safety-evaluable population (N=42), most participants (79%) had an International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) risk factor of intermediate or poor. Nearly half (46%) of the efficacy-evaluable population (N=24) achieved a confirmed response per RECIST 1.1, and only one patient had primary progressive disease. The vast majority of the efficacy-evaluable population remains on treatment. In the safety-evaluable population, no unexpected safety risks were identified at the time of DCO, and casdatifan plus cabozantinib had an acceptable safety profile with no meaningful overlapping toxicity for the two drugs. Only two patients discontinued any drug, and no patients discontinued treatment with both drugs. The incidence of treatment-emergent adverse events (TEAEs) with casdatifan, particularly anemia and hypoxia, was similar to TEAEs observed with casdatifan monotherapy, and there were no casdatifan-related Grade 4 or 5 adverse events. The incidence of TEAEs associated with each drug was consistent with what is expected for each drug alone. A summary of the efficacy and safety results is below. Efficacy-Evaluablea casdatifan 100mg QD + cabozantinib 60mg QD (n=24) Median Follow-Up 5.3 months Confirmed ORR (cORR) per RECIST v1.1 [95% CI] 46% (11)b [26,67] Best Overall Response: Complete Response 4% (1) Partial Response 42% (10)b Stable Disease 50% (12) Progressive Disease 4% (1) CI: confidence interval; QD: daily a All eligible patients who received any study treatment and reached a minimum of 12 weeks follow-up or discontinued due to progression or death. b Inclusive of one patient who had partial response confirmation after March 14, 2025. Safetya casdatifan 100mg QD + cabozantinib 60mg QD (n=42) casdatifan cabozantinib Patients with any Treatment-Related Grade ≥3 AEb Anemia 24% (10) 14% (6) Hyponatremia 0 7% (3) Hypoxia 7% (3) 0 Hypertension 0 5% (2) Neutrophil count decrease 2% (1) 5% (2) Patients with any AE leading to dose reductionb Fatigue 2% (1) 12% (5) Anemia 10% (4) 2% (1) Hypoxia 10% (4) 0 Palmar-plantar erythrodysesthesia 0 5% (2) Stomatitis 0 5% (2) AE: adverse event a Safety population included patients who received any amount of study drug and had at least one month of safety follow-up at the data cutoff date. b Treatment-emergent adverse events (grade 3 or higher) related to casdatifan, cabozantinib, or any study drug reported in ≥3% of patients in any treatment arm. Arcus is pursuing a broad development program in both the immuno-oncology (IO)-naive and post-IO settings with differentiated combinations to maximize the opportunity for casdatifan in ccRCC. These studies include: Arcus's planned Phase 3 study, PEAK-1, which will evaluate casdatifan plus cabozantinib versus cabozantinib monotherapy as a first- or second-line treatment in patients with metastatic ccRCC who have previously received anti-PD-1/PD-L1 therapy. The primary endpoint will be PFS with a key secondary endpoint of overall survival. eVOLVE-RCC02, a Phase 1b/3 study sponsored by AstraZeneca, which will evaluate casdatifan plus volrustomig, an investigational anti-PD-1/CTLA-4 bispecific antibody, as first-line treatment for participants with ccRCC. ARC-20, which includes three cohorts evaluating casdatifan in earlier-line settings, including casdatifan plus zimberelimab in first-line ccRCC, casdatifan monotherapy in favorable risk ccRCC, and casdatifan monotherapy in immunotherapy-experienced, TKI-naive settings. Investors may dial in to the conference call at +1 404 975 4839 (local) or +1 833 470 1428 (toll-free) using Conference ID: 446724 on Monday, June 2, 2025, at 5:00 AM PT / 7:00 AM CT. Participants may also register for the call online using the following link: To access the live webcast and accompanying slide presentation, please visit the "Investors & Media" section of the Arcus Biosciences website at A replay will be available following the live event. About Casdatifan (AB521) Casdatifan is a small-molecule inhibitor of HIF-2a, a transcription factor responsible for activating multiple tumor growth pathways in hypoxic and pseudo-hypoxic tumor environments. By selectively binding HIF-2a, casdatifan is designed to shut down hypoxic oncogenesis and key oncogenic pathways, which leads to cancer cell death. Clear cell renal cell carcinoma is almost universally associated with HIF-2a dysregulation. Casdatifan is currently being evaluated in ARC-20, a Phase 1/1b study in renal cell carcinoma. Casdatifan is an investigational molecule. Approval from any regulatory authority for its use has not been received, and its safety and efficacy have not been established. About RCC According to the American Cancer Society, kidney cancer is among the top 10 most commonly diagnosed forms of cancer among both men and women in the U.S., and an estimated 80,980 Americans will be diagnosed with kidney cancer in 2025. Clear cell RCC is the most common type of kidney cancer in adults. If detected in its early stages, the five-year survival rate for RCC is high; for patients with advanced or late-stage metastatic RCC, however, the five-year survival rate is only 18%. In 2022, approximately 32,200 patients with advanced kidney cancer required systemic therapy in the U.S., with over 20,000 patients receiving first-line treatment. About Arcus Biosciences Arcus Biosciences is a clinical-stage, global biopharmaceutical company developing differentiated molecules and combination therapies for people with cancer. In partnership with industry collaborators, patients and physicians around the world, Arcus is expediting the development of first- or best-in-class medicines against well-characterized biological targets and pathways and studying novel, biology-driven combinations that have the potential to help people with cancer live longer. Founded in 2015, the company has advanced multiple investigational medicines into registrational clinical trials including domvanalimab, an Fc-silent anti-TIGIT antibody being studied in combination with zimberelimab, an anti-PD-1 antibody, for upper gastrointestinal and non-small cell lung cancer, casdatifan, a HIF-2a inhibitor for clear cell renal cell carcinoma, and quemliclustat, a small-molecule CD73 inhibitor for pancreatic cancer. For more information about Arcus Biosciences' clinical and preclinical programs, please visit Forward Looking Statements This press release contains forward-looking statements. All statements regarding events or results to occur in the future contained herein are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, the statements in Dr. Choueiri's and Dr. Rosen's quotes and statements regarding: the potency, efficacy or safety of casdatifan, including its potential for a best-in-class profile and potential as a combination therapy; and Arcus's development plans for the casdatifan program, including expected timing and design for new studies and cohorts and plans for generating data to support initiation of future studies. All forward-looking statements involve known and unknown risks and uncertainties and other important factors that may cause Arcus's actual results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to risks associated with: interim data not being replicated in future studies evaluating the same investigational molecules or regimen; the unexpected emergence of adverse events or other undesirable side effects with casdatifan; risks associated with manufacturing or supplying product for such clinical trials; uncertainties in timelines associated with the conduct of clinical studies and with respect to the regulatory application process; difficulties associated with the management of the collaboration activities with our strategic partners or expanded clinical programs; changes in the competitive landscape for Arcus's programs; and the inherent uncertainty associated with pharmaceutical product development and clinical trials. Risks and uncertainties facing Arcus are described more fully in the "Risk Factors" section of Arcus's most recent periodic report filed with the U.S. Securities and Exchange Commission. You are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date of this press release. Arcus disclaims any obligation or undertaking to update, supplement or revise any forward-looking statements contained in this press release except to the extent required by law. The Arcus name and logo are trademarks of Arcus Biosciences, Inc. All other trademarks belong to their respective owners. View source version on Contacts Investor Inquiries: Pia EavesVP of Investor Relations & Strategy(617) 459-2006peaves@ Media Inquiries: Holli KolkeyVP of Corporate Affairs(650) 922-1269hkolkey@ Maryam BassiriAD, Corporate Communications(510) 406-8520mbassiri@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
